Navigation Links
Study shows continued success for new HPV vaccine against virus responsible for cervical cancer

reported each year, making it the most common sexually transmitted disease in the nation.

"Nearly all sexually active people are going to get exposed to the virus sometime during their lives," says Dr. Ault. "For most people, HPV causes no complications and goes away on its own. However, in some cases, if left untreated, certain high-risk types of HPV can lead to cervical cancer.

"The goal of the study was to see if we could prevent precancerous cases and we were 98 percent effective. Everyone who gets cancer goes through a pre-cancerous stage," says Ault. "There are about 50 to 60 million pap smears performed each year in the US, and about seven percent are abnormal. We spend about 3 billion dollars each year to find and treat these pre-cancerous stages caused by some type of HPV."

To date there is no vaccine specifically designed to treat disease that is already established. Dr. Ault explains the current HPV vaccine is meant to be a preventive or prophylactic vaccine Ð that's why it is given to adolescents.

Gardasil was approved by the U.S. Food and Drug Administration last year for use in females 9 to 26 years of age. While controversy has been raised about giving pre-adolescent girls a vaccine for a sexually transmitted disease, Dr. Ault argues, "young women, young girls make very good immune responses to this vaccine, so that will enhance their protection."

Researchers believe the vaccine will be effective in lowering a girl's lifetime risk of cervical cancer. To that end Merck launched the national "One Less" campaign last year, which encourages females eligible for the vaccine to begin their vaccination series of three shots over six months and to continue seeing their doctor for regular checkups and screenings.


'"/>

Source:Emory University


Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... who lived 2,330 years ago in the southernmost tip of ... when his DNA profile is one of the ,earliest diverged, ... region where modern humans are believed to have originated roughly ... ,mitochondrial DNA, was sequenced to provide clues to early modern ... that we all come from Africa, and helps us map ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... Hopkins researchers have created a synthetic protein that, when activated ... body where cancer, arthritis and other serious medical disorders can ... type of diagnostic imaging technology and may someday serve as ... where signs of disease have been found. In a study ...
... mood for food can be changed by a restaurant,s choice ... calorie intake, according to a new study., "When we did ... music and lighting led diners to eat 175 fewer calories ... Wansink, professor of marketing and director of Cornell University,s Food ...
... FARMINGTON, Conn., Aug. 29, 2012 /PRNewswire-iReach/ -- The biobanking market ... new drug and treatment development for specific diseases. The ... and is projected to increase by 30% between 2010 and ... Private sector biobanks will experience the greatest increase with growth ...
Cached Biology News:Collagen-seeking synthetic protein could lead doctors to tumor locations 2Collagen-seeking synthetic protein could lead doctors to tumor locations 3Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 2Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 3
(Date:9/29/2014)... emerging diseases and biodiversity loss requires evolutionary thinking, ... Science Express that was co-authored by Bruce ... Agriculture and Life Sciences. , For the first ... reviewed progress in addressing a broad set of ... approaches that consider evolutionary histories and the likelihood ...
(Date:9/29/2014)... Albany,NY (PRWEB) September 29, 2014 Transparency ... (by Synthesis - SPPS, LPPS, HPPS, by Application - ... Innovative & Generic and by Delivery) - Global Industry ... 2018’, states that the global peptide therapeutics market was ... reach US$25.4 billion by 2018 at an 8.7% CAGR. ...
(Date:9/29/2014)... SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life ... products for advanced microarray diagnostics, is pleased to announce ... of the Board of Directors of SQI, replacing ... as a Director on the Board and will continue ... "We are very pleased to have Mr. Winkley assume ...
(Date:9/29/2014)... ZIONA, Israel , September 29, ... stage company developing novel immunomodulators for severe infections, today ... ( BARDA ) has awarded Atox Bio with a ... for the development of AB103 to treat Necrotizing Soft ... and public health threats that end in sepsis. ...
Breaking Biology Technology:Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3SQI Diagnostics Announces New Chairman of Board of Directors 2Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2
... , , SAN FRANCISCO, Aug. 4 Nile ... the development of novel therapeutics for heart failure patients, today announced ... of its lead product, CD-NP, for the treatment of acute heart ... study is designed to provide additional information on the safety and ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. ... planning and implementing the clinical development program for the ... is an experienced oncologist who brings an extensive background ...
... , PALO ALTO, Calif., August ... antiviral therapies, announced today that it has licensed the exclusive ... Stanford University. This technology, discovered in the lab of Stanford ... focused on a variety of novel targets, including key features ...
Cached Biology Technology:Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 2Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 3Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 2Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 3Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University 2
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
WIF-1 (N-20)...
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Biology Products: